Saturday 17 October 2026
Export YARW’s income statement to Excel — free account
Yarrow Bioscience, Inc
YARW Healthcare Biotechnology
Yarrow Bioscience, Inc’s revenue for fiscal 2025 (year ended December 2025) was $570,000.00, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 40.6%, EPS grew 67.1% and free cash flow grew 81.6%, each against the same quarter a year earlier.
18.78
1.22
−6.10%
Follow YARW
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (61.40%) | (62.40%) | (66.33%) | (70.42%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 4 | 3 | 3 | |
| (54.77%) | (52.15%) | (54.57%) | (59.94%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(84.80%) | (87.09%) | (95.59%) | (105.42%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(19.74) | (30.10) | (38.72) | (44.81) | |
Free Cash Flow |
(16.93) | (25.74) | (33.12) | (38.36) | |
| Other line items | |||||
Cash ROIC |
(37.64%) | (51.94%) | (58.34%) | (59.21%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,040.87% | 3,068.28% | 3,374.91% | 4,951.34% | |
Selling, General and Administrative Expense of Revenue |
2,193.57% | 2,399.12% | 1,944.21% | 2,267.18% | |
Share Based Compensation of Revenue |
399.59% | 444.71% | 404.91% | 472.90% | |
Operating CF/Net income |
0.91 | 1.20 | 1.25 | 1.14 | |
Depreciation/Fixed assets |
(3.05) | (5.35) | (8.39) | (12.60) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.56 | 0.53 | 0.67 | 0.61 | |
Operating CF per Share |
(19.74) | (30.10) | (38.72) | (44.81) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates